Euractiv Argues EU Cosmetics Rules Should Weigh Real Risk

A commentary published by Euractiv, titled "Effective Cosmetics Regulation Starts with Real-World Risk," argues that European Union cosmetics rules work best when they are built around how much of an ingredient a person is actually exposed to, rather than whether that ingredient carries a hazard label at all. The distinction sounds technical, but it shapes which products stay on EU shelves and which get reformulated.

What Is the Difference Between Hazard and Risk?

In regulatory toxicology, "hazard" describes whether a substance can cause harm under some condition, at some dose, in some form of exposure. "Risk" describes the actual likelihood of harm given how the substance is used in the real product — the concentration, how often it is applied, and whether it stays on skin or is rinsed off. A commentary framed around "real-world risk," as the Euractiv headline puts it, is arguing that regulation should sort ingredients by the second measure rather than the first.

This matters because a substance can be classified as hazardous in a laboratory setting at high, sustained, or ingested doses while posing negligible risk in a leave-on lotion used a few times a week at low concentration. Regulators, industry groups, and consumer advocates have long disagreed over where that line should be drawn, and the Euractiv piece adds to that ongoing argument.

How Does Concentration Already Shape Cosmetics Rules?

Skincare offers a familiar, concrete example of risk-based thinking already in practice: retinoids. As explained in Rey's Refined Radiance's comparison of retinol and retinal, the same class of vitamin A derivative behaves differently depending on concentration and formulation, which is why products list percentage strength and carry usage guidance rather than being banned outright. That is a risk-based approach in miniature: the ingredient itself is not prohibited, but its permitted concentration and labeling are calibrated to reduce irritation and photosensitivity risk in ordinary use.

The cosmetics industry has pointed to this kind of dose-dependent regulation as the model it wants applied more broadly — arguing that ingredients should be assessed for how they perform in a finished product at typical use levels, not flagged simply because a hazard classification exists somewhere in a technical dossier.

Why Do Critics Push Back on a Purely Risk-Based Model?

Consumer and public-health advocates have historically argued the opposite case in EU chemical and cosmetics debates: that hazard-based cutoffs are simpler to enforce, harder to game through reformulation loopholes, and more protective when long-term or combined exposure data is incomplete. Under a strict hazard approach, a substance identified as carcinogenic, mutagenic, or reprotoxic can be restricted regardless of the concentration a manufacturer proposes, on the theory that dose-response data can be uncertain, contested, or slow to produce. Euractiv's framing of the debate as one of "effective" regulation implies a rebuttal to that caution — suggesting that hazard-only rules can end up restricting ingredients that pose little practical danger in the way they are actually formulated and sold.

What Would a Risk-Based Standard Change in Practice?

If EU policymakers shifted further toward the risk-based framing the commentary describes, the practical effects would likely show up in three places: which ingredients require reformulation versus which simply require dosage caps and labeling; how quickly new ingredients can clear approval once exposure modeling is submitted; and how disputes between industry trade groups and EU health bodies get resolved when hazard data and real-world exposure data point in different directions.

Glossary

• Hazard-based regulation: Restricts a substance based on its intrinsic capacity to cause harm, independent of use conditions.
• Risk-based regulation: Restricts or permits a substance based on the calculated likelihood of harm given actual concentration, exposure route, and frequency of use.
• Exposure modeling: The scientific estimate of how much of an ingredient a consumer's skin or body actually absorbs under normal product use.

What to Watch

• Whether EU consumer-safety bodies respond publicly to arguments for a more exposure-driven review process.
• Whether cosmetics trade associations cite real-world exposure data in future ingredient-approval submissions.
• Whether any EU member state or the European Commission proposes formal changes to how hazard classifications translate into cosmetics restrictions.
• How brands using dose-sensitive ingredients, such as retinoids, adjust labeling if exposure-based standards gain traction.

The original commentary is available via Euractiv.